Evogene

Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evogene reports revenue growth and strategic collaborations driving future prospects

Evogene's Q1 2024 performance showed revenue growth, decreased losses, and strategic milestones achieved by key subsidiaries.
The company's strengths lie in innovative collaborations, a unique CPB platform, and successful revenue-driving partnerships.
Challenges include financial management, operational execution, and logistical considerations for seed supply.
Opportunities for growth stem from promising future achievements, strategic partnerships, and market differentiation through innovation.

Evogene reports revenue surge and promising developments in key segments

Evogene demonstrated strong revenue growth in the first half of 2024 and made progress in reducing losses, reflecting improving financial performance.
Casterra's expanding market reach and revenue growth opportunities, coupled with Biomica's promising trial results, position Evogene well for future growth.
While facing challenges in achieving profitability and managing cash flow, Evogene's focus on operational efficiency and market expansion presents avenues for sustainable growth.

Evogene reports Q3 revenue decline but anticipates growth opportunities

Evogene's Q3 2024 performance reflected a decline in revenues but improved cost management, with a focus on enhancing cash reserves.
The company's strengths lie in upcoming revenue growth, strategic collaborations, and plans to fortify its financial position.
Challenges include market uncertainties, operational losses, and addressing investor concerns for sustained growth and profitability.
Opportunities exist for Evogene to capitalize on its achievements, explore new avenues, and drive value creation for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Preliminary data from Biomica's Phase 1 study of BMC128 will be showcased at the conference REHOVOT, Israel , April 16, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

REHOVOT, Israel , April 11, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting

Finally Foods is financed by the Israeli Innovation Authority (IIA) and The Kitchen Hub, and will be granted a license to utilize Evogene's AI technology REHOVOT, Israel , April 2, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments and The Kitchen FoodTech Hub (TKH), the foodtech incubator and investment arm of Israeli food giant Strauss Group, have jointly announced the establishment of Finally Foods Ltd.

Evogene and The Kitchen FoodTech Hub by Strauss Group Established Finally Foods Ltd. - Revolutionizing Protein Production in Plants for the Food Industry

REHOVOT, Israel , March 28, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science-based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2023, with the Securities and Exchange Commission.

Evogene Announces Filing of Annual Report on Form 20-F

REHOVOT, Israel , March 20, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, today reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares has been below $1.00 per share for the last 30 consecutive business days.

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

REHOVOT, Israel , March 19, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd.

Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing

REHOVOT, Israel , March 13, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products and a subsidiary of Evogene Ltd.

Lavie Bio and Ceres Global Ag Corp. Collaborate to Include YalosTM Bio-Inoculant, in Regenerative Agriculture Initiatives in North America

Evogene Ltd. (NASDAQ:EVGN ) Q4 2023 Results Conference Call March 7, 2024 9:00 AM ET Company Participants Ofer Haviv - President and Chief Executive Officer Yaron Eldad - Chief Financial Officer Yoash Zohar - CEO of Casterra Conference Call Participants Ben Klieve - Lake Street Capital Ben Haynor - Alliance Global Partners Brett Reiss - Janney Montgomery Scott Operator Ladies and gentlemen, thank you for standing by.

Evogene Ltd. (EVGN) Q4 2023 Earnings Call Transcript

Evogene (EVGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.07 per share a year ago.

Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates

Conference call and webcast: today, March 7, 2024, 9:00 am E.T. +1-888-407-2553 or +972-3- 9180608 I https://veidan.activetrail.biz/evogeneq4-2023 REHOVOT, Israel , March 7, 2024 /PRNewswire/ -- Evogene Ltd.

Evogene Reports Fourth Quarter and Full Year 2023 Financial Results

Corteva Inc

REHOVOT, Israel , March 6, 2024 /PRNewswire/ -- AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of Evogene Ltd.

AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides

The new agreements are expected to support additional production of approximately 400 tons of Casterra's elite castor seeds in 2024 and establish long-term production infrastructure REHOVOT, Israel , March 5, 2024 /PRNewswire/ -- Casterra Ag Ltd., an integrated solutions company for growing castor seeds for bio-based industries, such as biofuels, biopolymers, and a subsidiary of Evogen Ltd.

Casterra Announces New Agreements with Seed Producers in Brazil and Africa to Meet Growing Demand for its Elite Castor Seed Varieties

The payment completes the $5M advance payment received under the licensing agreement for bio-fungicide product candidates REHOVOT, Israel , Feb. 28, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products, and a subsidiary of Evogene Ltd.

Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M after Meeting Corteva's Licensing Agreement Requirements

Conference call scheduled for 9:00 AM ET REHOVOT, Israel , Feb. 26, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that it will release its financial results for the third quarter of 2023, on Thursday, March 7 th, 2024.

Evogene Schedules Fourth Quarter 2023 Financial Results Release & Conference Call for March 7th, 2024

REHOVOT, Israel , Feb. 22, 2024 /PRNewswire/ -- AgPlenus Ltd, a global leader in designing and developing novel sustainable crop protection products, and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), is pleased to announce the appointment of Dr. Dan Jacob Gelvan as its new Chief Executive Officer effective as of February 19, 2024.

AgPlenus Announces Appointment of Dr. Dan Jacob Gelvan as its Incoming Chief Executive Officer

The collaboration will tap into the potential of artificial intelligence (AI) to design and optimize crop protection chemistry, developing a novel sustainable Mode-of-Action (MoA) broad-spectrum herbicide for farmers REHOVOT, Israel , Feb. 21, 2024 /PRNewswire/ -- AgPlenus Ltd., a global leader in designing and developing novel sustainable crop protection products and a subsidiary of Evogene Ltd.

AgPlenus Announces Licensing & Collaboration Agreement with Bayer to Develop a New Sustainable Weed Control Solution

Agreement reinforces both companies' commitment to developing and bringing innovative biological solutions to farmers BASEL, Switzerland and REHOVOT, Israel , Feb. 20, 2024 /PRNewswire/ -- Syngenta Crop Protection, a leader in agricultural innovation, and Lavie Bio Ltd., a leading ag-biologicals company and a subsidiary of Evogene Ltd.

Syngenta and Lavie Bio Announce Partnership to Discover and Develop Novel Bio-Insecticide

The parties will identify and design probiotic bacteria that produce highly sustainable quantities of microbial metabolites, known to improve human health and vitality BOSTON and REHOVOT, Israel , Feb. 6, 2024 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product development across multiple market segments, and Verb Biotics LLC.

Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation

REHOVOT, Israel , Jan. 23, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica CEO Set to Engage in Panel Discussion at 8th Annual European Microbiome Movement Summit

The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica's microbiome-based immuno-oncology drug, BMC128 REHOVOT, Israel , Jan. 17, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug

Does Evogene (EVGN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy

REHOVOT, Israel , Dec. 21, 2023 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.

Biomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024

Mr. Yoash Zohar, a seasoned ag executive, is joining Casterra as CEO to lead the company's significant operational expansion REHOVOT, Israel , Dec. 19, 2023 /PRNewswire/ -- Casterra Ag Ltd., a subsidiary of Evogene Ltd.

Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation

The agreement supports  Lavie Bio's 2024 sales growth plan for spring wheat, durum, and barley in Canada REHOVOT, Israel , Dec. 5, 2023 /PRNewswire/ -- Lavie Bio Ltd., a subsidiary of Evogene Ltd.

Lavie Bio Announces a Distribution Agreement with WinField United Canada for its Bio-Inoculant Seed Treatment Yalos™

After losing some value lately, a hammer chart pattern has been formed for Evogene (EVGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

News for Evogene Stock (EVGN)